Invivyd Announces Pricing of $50 Million Public Offering of Common Stock and Pre-Funded Warrants

▤ Summary

Invivyd priced an underwritten public offering of common stock and pre-funded warrants that is expected to raise about $50 million before fees and expenses. The company also granted underwriters a 30-day option to buy additional shares. Invivyd plans to use the proceeds for development of its VYD2311 clinical program, research and development across pipeline programs, SPEAR study efforts, and general corporate purposes. The company remains focused on antiviral and monoclonal antibody work in infectious diseases and related long COVID research.

$ Funding

▦ Linked Companies